Results 31 to 40 of about 6,107 (224)

Terlipressin— [PDF]

Intensivmedizin und Notfallmedizin, 2005
The vasopressing agent terlipressin is a commonly used drug with various indications especially in patients with advanced cirrhosis. Being a potent vasoconstrictor it increases the systemic vascular pressure especially inthe splanchnic area, resulting in a decrease of portal pressure. Due to complex pathophysiologic patterns, different complications of
T. Brünnler, F. Mandraka, J. Langgartner   +2 more
openaire   +2 more sources

Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study

Renal Failure, 2022
Purpose Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.Materials and Methods This pilot ...
Jinlong Wang, Mengjuan Shi, Lili Huang, Qing Li, Shanshan Meng, Jingyuan Xu, Ming Xue, Jianfeng Xie, Songqiao Liu, Yingzi Huang   +9 more
doaj   +1 more source

Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

Ain Shams Journal of Anesthesiology, 2020
Background and objectives Preoperative use of renin angiotensin system antagonists has been considered an independent risk factor for development of vasoplegic syndrome.
Mohamed Saleh, Sherine Kamal Zaki Kodeira, Abdelkhalek Abdelmoneim Aboulseoud   +2 more
doaj   +1 more source

Improvement of gut-vascular barrier by terlipressin reduces bacterial translocation and remote organ injuries in gut-derived sepsis

Frontiers in Pharmacology, 2022
Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis
Zenan Chang, Zenan Chang, Yinan Zhang, Ming Lin, Shihong Wen, Hanjin Lai, Yaqing Zhan, Xiufen Zhu, Zhikun Huang, Xuyu Zhang, Zimeng Liu   +10 more
doaj   +1 more source

Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient

Kaohsiung Journal of Medical Sciences, 2013
Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang, Daw-Yang Hwang, Sophie S.W. Wang, Shang-Jyh Hwang, Li-Tzong Chen, Mei-Chuan Kuo   +5 more
doaj   +1 more source

Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review

Proceedings of Singapore Healthcare, 2011
Background: Vasodilatory septic shock unresponsive to fluid resuscitation requires the addition of vasopressors. Catecholamines remain the first line vasopressor therapy, but treatment failure is a potential problem.
Jie Lin Soong BSc (Pharm) (Hons), Wai Hing Lim B Pharm (Hons), M Clin Pharm   +1 more
doaj   +1 more source

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico

Annals of Hepatology, 2009
Introduction. Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.Aim.
Linda E. Muñoz, Eliud G. Alcalá, Paula Cordero, Manuel A. Martinez, Nathalie Y. Vázquez, Susana Galindo, Eduardo Mendoza, José J. Segura   +7 more
doaj   +1 more source

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Contemporary Clinical Trials Communications, 2023
Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of
Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy   +14 more
doaj   +1 more source

Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites

GastroHep, 2022
Background. Terlipressin is a long acting synthetic analogue of vasopressin, which is used to manage variceal bleeding and hepatorenal syndrome.
Jasmohan S. Bajaj, James H. Fischer, Patrick Yeramian, Edith A. Gavis, Andrew Fagan, Paolo Angeli, Guadalupe Garcia-Tsao, Jonathan M. Adams, Penelope Markham   +8 more
doaj   +1 more source

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile

Gastroenterology Insights, 2023
Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of
Ahlam Ayyad, Rami A. Al-Horani
doaj   +1 more source